000 02570 a2200853 4500
005 20250516222506.0
264 0 _c20140811
008 201408s 0 0 eng d
022 _a0394-6320
024 7 _a10.1177/039463201402700201
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aTotaro, R
245 0 0 _aNatalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy.
_h[electronic resource]
260 _bInternational journal of immunopathology and pharmacology
_c
300 _a147-54 p.
_bdigital
500 _aPublication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAntibodies, Monoclonal, Humanized
_xadverse effects
650 0 4 _aDisability Evaluation
650 0 4 _aDisease Progression
650 0 4 _aDisease-Free Survival
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aImmunosuppressive Agents
_xadverse effects
650 0 4 _aItaly
650 0 4 _aKaplan-Meier Estimate
650 0 4 _aMagnetic Resonance Imaging
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aMultiple Sclerosis, Relapsing-Remitting
_xdiagnosis
650 0 4 _aNatalizumab
650 0 4 _aProduct Surveillance, Postmarketing
650 0 4 _aTime Factors
650 0 4 _aTreatment Outcome
700 1 _aLugaresi, A
700 1 _aBellantonio, P
700 1 _aDanni, M
700 1 _aCostantino, G
700 1 _aGasperini, C
700 1 _aFlorio, C
700 1 _aPucci, E
700 1 _aMaddestra, M
700 1 _aSpitaleri, D
700 1 _aLus, G
700 1 _aArdito, B
700 1 _aFarina, D
700 1 _aRossi, M
700 1 _aDi Carmine, C
700 1 _aAltobelli, E
700 1 _aMaccarone, B
700 1 _aCasalena, A
700 1 _aDe Luca, G
700 1 _aTravaglini, D
700 1 _aDi Ioia, M
700 1 _aDi Tommaso, V
700 1 _aFantozzi, R
700 1 _aRuggieri, S
700 1 _aProvinciali, L
700 1 _aDe Riso, S
700 1 _aMundi, C
700 1 _aFuiani, A
700 1 _aGalgani, S
700 1 _aRuggieri, S
700 1 _aManiscalco, G T
700 1 _aGiuliani, G
700 1 _aCartechini, E
700 1 _aPetretta, V
700 1 _aFratta, M
700 1 _aAlfieri, G
700 1 _aGatto, M
700 1 _aCarolei, A
773 0 _tInternational journal of immunopathology and pharmacology
_gvol. 27
_gno. 2
_gp. 147-54
856 4 0 _uhttps://doi.org/10.1177/039463201402700201
_zAvailable from publisher's website
999 _c23990631
_d23990631